MML Investors Services LLC Buys 2,985 Shares of Innoviva, Inc. (NASDAQ:INVA)

MML Investors Services LLC raised its stake in shares of Innoviva, Inc. (NASDAQ:INVA) by 19.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 18,375 shares of the biotechnology company’s stock after purchasing an additional 2,985 shares during the quarter. MML Investors Services LLC’s holdings in Innoviva were worth $355,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Jane Street Group LLC raised its stake in shares of Innoviva by 46.4% in the third quarter. Jane Street Group LLC now owns 136,361 shares of the biotechnology company’s stock valued at $2,633,000 after purchasing an additional 43,218 shares in the last quarter. Systematic Financial Management LP boosted its stake in Innoviva by 4.7% during the third quarter. Systematic Financial Management LP now owns 1,979,073 shares of the biotechnology company’s stock worth $38,216,000 after buying an additional 89,633 shares in the last quarter. Walleye Capital LLC bought a new stake in Innoviva in the 3rd quarter valued at $214,000. Martingale Asset Management L P raised its stake in shares of Innoviva by 0.7% in the 3rd quarter. Martingale Asset Management L P now owns 77,842 shares of the biotechnology company’s stock valued at $1,503,000 after buying an additional 550 shares in the last quarter. Finally, FMR LLC lifted its holdings in shares of Innoviva by 8.2% during the 3rd quarter. FMR LLC now owns 10,119 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 771 shares during the period. Institutional investors and hedge funds own 99.12% of the company’s stock.

Innoviva Price Performance

Shares of Innoviva stock opened at $17.78 on Wednesday. The firm has a market cap of $1.11 billion, a P/E ratio of 25.77 and a beta of 0.53. The firm’s 50-day simple moving average is $19.23 and its 200-day simple moving average is $18.55. Innoviva, Inc. has a twelve month low of $14.32 and a twelve month high of $21.28. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.64 and a current ratio of 1.79.

Innoviva (NASDAQ:INVA) last released its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.27 by ($0.25). The company had revenue of $89.51 million during the quarter. Innoviva had a net margin of 18.31% and a return on equity of 20.84%. As a group, research analysts expect that Innoviva, Inc. will post 0.33 EPS for the current fiscal year.

Innoviva Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.